Briacell Therapeutics financials
$4.28+4.90%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jul 31 | FY24 Jul 31 | FY23 Jul 31 | FY22 Jul 31 | FY21 Jul 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$27.2M | -$33.3M | -$23.3M | -$15.3M | -$7.0M |
| Net income | -$26.3M | -$4.8M | -$20.3M | -$26.8M | -$13.8M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-62.19 | $-43.68 | $-1.30 | $-1.73 | $-3.06 |
| EBITDA | -$27.1M | -$33.2M | -$23.3M | -$15.3M | -$7.0M |
| Operating cash flow | -$28.2M | -$24.1M | -$23.7M | -$12.5M | -$7.8M |
| Free cash flow | -$28.2M | -$24.6M | -$23.7M | -$12.5M | — |
| Diluted shares | 0.4M | 0.1M | 15.6M | 15.5M | 4.5M |
Balance sheet
| Period end | Jul 31 | Jul 31 | Jul 31 | Jul 31 | Jul 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $10.5M | $862.1K | $21.3M | $41.0M | $57.3M |
| Short-term investments | $7.4M | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $26.0K |
| Total assets | $21.6M | $5.9M | $27.2M | $42.6M | $58.0M |
| Total liabilities | $4.3M | $8.6M | $30.9M | $32.2M | $30.4M |
| Shareholders' equity | $17.3M | -$2.7M | -$3.8M | $10.3M | $27.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology